4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 112 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q3 2023. The put-call ratio across all filers is 0.97 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $51,014,367 | -29.6% | 4,007,413 | 0.0% | 1.38% | -31.8% |
| Q2 2023 | $72,413,953 | +5.1% | 4,007,413 | 0.0% | 2.02% | -19.9% |
| Q1 2023 | $68,887,429 | -22.6% | 4,007,413 | 0.0% | 2.52% | -33.0% |
| Q4 2022 | $89,004,643 | +176.2% | 4,007,413 | 0.0% | 3.76% | +182.2% |
| Q3 2022 | $32,220,000 | +15.2% | 4,007,413 | 0.0% | 1.33% | -1.5% |
| Q2 2022 | $27,972,000 | -30.6% | 4,007,413 | +50.4% | 1.35% | -16.2% |
| Q1 2022 | $40,288,000 | -8.5% | 2,664,521 | +32.8% | 1.61% | +0.9% |
| Q4 2021 | $44,009,000 | -18.6% | 2,005,862 | 0.0% | 1.60% | -24.3% |
| Q3 2021 | $54,098,000 | +12.0% | 2,005,862 | 0.0% | 2.11% | +16.6% |
| Q2 2021 | $48,301,000 | +8.0% | 2,005,862 | +94.5% | 1.81% | +7.9% |
| Q1 2021 | $44,728,000 | -2.4% | 1,031,070 | -6.8% | 1.68% | -7.0% |
| Q4 2020 | $45,847,000 | – | 1,106,070 | – | 1.80% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 945,382 | $22,765,000 | 5.92% |
| Octagon Capital Advisors LP | 831,267 | $20,017,000 | 4.15% |
| BVF INC/IL | 2,005,862 | $48,301,000 | 1.81% |
| Casdin Capital, LLC | 1,115,555 | $26,863,000 | 0.68% |
| Eagle Health Investments LP | 57,090 | $1,375,000 | 0.47% |
| Soleus Capital Management, L.P. | 100,800 | $2,427,000 | 0.37% |
| VIKING GLOBAL INVESTORS LP | 3,937,914 | $94,825,000 | 0.29% |
| ArrowMark Colorado Holdings LLC | 1,029,897 | $24,800,000 | 0.19% |
| Perceptive Advisors | 750,512 | $18,072,000 | 0.12% |
| Virtus ETF Advisers LLC | 7,642 | $184,000 | 0.08% |